ストックスクリーナーアプリを入手
298.28
1.75%
4.7586
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $527 - Moomoo
Canaccord reiterates Alnylam stock Buy rating after RNAi event By Investing.com - Investing.com Canada
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
ALNY Maintains Buy Rating -- Price Target Lowered by HC Wainwrig - GuruFocus
H.C. Wainwright cuts Alnylam stock price target to $470 on revenue estimates - Investing.com Canada
Number of shareholders of Alnylam Pharmaceuticals, Inc – BX:DUL - TradingView
Price to sales forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Enterprise value to EBITDA forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Alnylam Pharmaceuticals, Inc Actuals & Estimates (NASDAQ:ALNY) - TradingView
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
Biopharma bites: Ionis' rare disease deal, Vaxart's COVID-19 funding, Alnylam's AI embrace and more from Definium - FirstWord Pharma
Enterprise value to EBIT forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
ALNY Forecast — Price Target — Prediction for 2027 - TradingView
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh - TradingView
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding DisordersSlideshow (NASDAQ:ALNY) 2026-06-25 - Seeking Alpha
Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform - marketscreener.com
Alnylam Pharmaceuticals Inc RNAi Roundtable Webcast Transcript - GuruFocus
Price to earnings forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform - Business Wire
Oppenheimer Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $500 - Moomoo
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Jun 2026 $ALNY - MarketBeat
Why (ALNY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $370 - Moomoo
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership - Insider Monkey
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery - Yahoo Finance
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Sahm
Dyne Therapeutics adds ex-Sage CEO Barry Greene to board - Stock Titan
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries - Insider Monkey
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum - ChartMill
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
Alnylam Pharmaceuticals (ALNY) Investor Outlook: A Biotech Leader with 56.90% Upside Potential - DirectorsTalk Interviews
Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock - Insider Monkey
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers - ChartMill
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals Inc - TradingKey
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam expands Genesis Pharma collaboration in Europe - MSN
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets - Yahoo Finance
Understanding Momentum Shifts in (ALNY) - Stock Traders Daily
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - BioSpace
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - The Globe and Mail
Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
What Does the Alnylam-Inceptive AI Deal Entail - Kavout
Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets - World Business Outlook
1.53%
1.93%
大文字化:
|
ボリューム (24 時間):